1
1 of 3
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Bridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecology OncologySmilow Cancer Hospital at Trumbull5520 Park Avenue, Ste 1-200Trumbull, CT 06611
Blair McNamara, MD
she/her/hers
Gynecologic Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Obstetrics & Gynecology
Biography
Blair C. McNamara, MD, is an obstetrician-gynecologist specializing in gynecologic oncology. She focuses on diagnosing and treating cancers of the female reproductive system, with particular attention to providing comprehensive care for patients facing these conditions. She offers individually tailored treatments that range from surgical interventions to minimally invasive procedures.
As an assistant professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. McNamara conducts research aimed at understanding rare cervical cancers and developing new therapeutic strategies.
Dr. McNamara received her medical degree from Yale School of Medicine, and completed her residency in obstetrics and gynecology at the University of California San Francisco.
Titles
- Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- FellowshipYale School of Medicine (2025)
- ResidencyUniversity of California San Francisco (2022)
- MDYale School of Medicine (2018)
- BSBrown University, Human Biology (2012)
Additional Information
Honors & Recognitions
- José Asis Memorial Teaching Award: Yale School of Medicine (2025)
Board Certifications
- AB of Obstetrics & Gynecology, Obstetrics & Gynecology (2025)
Publications
- Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.
- Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.
- Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.
- Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.
- Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.
- Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.
- Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.
- Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.
- McNamara B, Abozenah Y, Goreshnik A, Liu C, Altwerger G. Utility of positron emission tomography in preoperative inguinal lymph node assessment for vulvar cancer in the GROINS-VII/sentinel lymph node biopsy era: A single institution retrospective analysis. Gynecologic Oncology 2025, 200: s30. DOI: 10.1016/j.ygyno.2025.04.565.
- Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.
- Greenman M, McNamara B, Ettorre V, Buza N, Azodi M. Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor. Gynecologic Oncology Reports 2025, 59: 101778. PMID: 40585380, PMCID: PMC12205314, DOI: 10.1016/j.gore.2025.101778.
- Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.
- Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.
- Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.
- Vlamis C, Abozenah Y, Pebley N, Chang Y, McNamara B, Altwerger G. Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. International Journal Of Gynecological Cancer 2024, 34: 1474-1475. PMID: 38724238, DOI: 10.1136/ijgc-2024-005358.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Greenman M, McNamara B, Mutlu L, Santin A. Entering the golden age for antibody-drug conjugates in gynecologic cancer. Oncoscience 2024, 11: 51-52. PMID: 38770444, PMCID: PMC11104406, DOI: 10.18632/oncoscience.604.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Greenman M, McNamara B, Mutlu L, Santin A. Targeting cervical cancer with anti-PD-1 antibodies: what is new? Expert Opinion On Biological Therapy 2024, 24: 111-114. PMID: 38391293, DOI: 10.1080/14712598.2024.2323596.
- McNamara B, Greenman M, Pebley N, Mutlu L, Santin A. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules 2023, 28: 7389. PMID: 37959808, PMCID: PMC10650896, DOI: 10.3390/molecules28217389.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, PMCID: PMC12626252, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.
- McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Mutlu L, Manavella D, Gullo G, McNamara B, Santin A, Patrizio P. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers 2022, 14: 5187. PMID: 36358604, PMCID: PMC9656291, DOI: 10.3390/cancers14215187.
- McNamara B, Joudeh L, Corbetta-Rastelli C, Orlando M, Kerns J. Traveling to California from out of state to receive abortion services at a hospital-based clinic: A qualitative study of people’s experiences. Sexual & Reproductive Healthcare 2022, 34: 100784. PMID: 36219955, DOI: 10.1016/j.srhc.2022.100784.
- McNamara B, Guerra R, Qin J, Craig A, Chen L, Varma M, Chapman J. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology Reports 2021, 38: 100870. PMID: 34646929, PMCID: PMC8496105, DOI: 10.1016/j.gore.2021.100870.
- Robledo-Gil T, Kemet S, Pensak M, Cutler A, McNamara B, Kennedy HP, Lundsberg L, Gariepy A. “Un abrazo a la distancia”: An Exploration of Spanish-Speaking Women’s Experiences with Pregnancy and Social Isolation in an Urban U.S. Setting. Hispanic Health Care International 2021, 20: 107-114. PMID: 34520260, DOI: 10.1177/15404153211041013.
- Webster E, Sartor R, Yadav G, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Ratner E, Altwerger G. Legal concerns and perceptions among women with gynecologic malignancies using prescribed medical cannabis: a single-institution, survey-based study. Gynecologic Oncology 2021, 162: s196-s197. DOI: 10.1016/s0090-8258(21)01023-4.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Webster E, Dugan K, McNamara B, Lu L, Azodi M, Ratner E, Schwartz P, Menderes G. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study. Gynecologic Oncology 2020, 159: 131. DOI: 10.1016/j.ygyno.2020.05.163.
- Dugan K, McNamara B, Lu L, Litkouhi B, Azodi M, Schwartz P, Ratner E, Menderes G, Silasi D. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer. Gynecologic Oncology 2019, 154: 152. DOI: 10.1016/j.ygyno.2019.04.358.
- McNamara BC, Cutler A, Lundsberg L, Kennedy HP, Gariepy A. “I’m used to doing it by myself”: exploring self-reliance in pregnancy. BMC Pregnancy And Childbirth 2018, 18: 393. PMID: 30290785, PMCID: PMC6173858, DOI: 10.1186/s12884-018-2022-8.
- Kerns J, Light A, Dalton V, McNamara B, Steinauer J, Kuppermann M. Decision satisfaction among women choosing a method of pregnancy termination in the setting of fetal anomalies and other pregnancy complications: A qualitative study. Patient Education And Counseling 2018, 101: 1859-1864. PMID: 29980336, DOI: 10.1016/j.pec.2018.06.012.
- Kerns J, Mengesha B, McNamara B, Cassidy A, Pearlson G, Kuppermann M. Effect of counseling quality on anxiety, grief, and coping after second-trimester abortion for pregnancy complications. Contraception 2018, 97: 520-523. PMID: 29477632, DOI: 10.1016/j.contraception.2018.02.007.
- McNamara B, Russo J, Chaiken S, Jacobson J, Kerns J. A qualitative study of digoxin injection before dilation and evacuation. Contraception 2018, 97: 515-519. PMID: 29477630, DOI: 10.1016/j.contraception.2018.02.004.
- Cutler A, McNamara B, Qasba N, Kennedy HP, Lundsberg L, Gariepy A. “I Just Don't Know”: An Exploration of Women's Ambivalence about a New Pregnancy. Women's Health Issues 2017, 28: 75-81. PMID: 29108986, PMCID: PMC6223118, DOI: 10.1016/j.whi.2017.09.009.
- McNamara BC, Losikoff PT, Huguenin L, Macalino GE, Rich JD, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2014, 91: 376-82. PMID: 23722268, PMCID: PMC3978152, DOI: 10.1007/s11524-013-9807-x.
Departments and Programs
Locations
1
1 of 3
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Bridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecology OncologySmilow Cancer Hospital at Trumbull5520 Park Avenue, Ste 1-200Trumbull, CT 06611
Biography
Blair C. McNamara, MD, is an obstetrician-gynecologist specializing in gynecologic oncology. She focuses on diagnosing and treating cancers of the female reproductive system, with particular attention to providing comprehensive care for patients facing these conditions. She offers individually tailored treatments that range from surgical interventions to minimally invasive procedures.
As an assistant professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. McNamara conducts research aimed at understanding rare cervical cancers and developing new therapeutic strategies.
Dr. McNamara received her medical degree from Yale School of Medicine, and completed her residency in obstetrics and gynecology at the University of California San Francisco.
Titles
- Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences
Education & Training
- FellowshipYale School of Medicine (2025)
- ResidencyUniversity of California San Francisco (2022)
- MDYale School of Medicine (2018)
- BSBrown University, Human Biology (2012)
Additional Information
Honors & Recognitions
- José Asis Memorial Teaching Award: Yale School of Medicine (2025)
Board Certifications
- AB of Obstetrics & Gynecology, Obstetrics & Gynecology (2025)
Publications
- Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.
- Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.
- Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.
- Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.
- Greenman M, Demirkiran C, McNamara B, Altwerger G, Ratner E, Santin A, Papatla K, Dottino P, Azodi M, Schwartz P, Clark M. Role of systematic lymphadenectomy at the time of cytoreductive surgery among non-high grade serous epithelial ovarian cancers. Gynecologic Oncology 2025, 200: 239-240. DOI: 10.1016/j.ygyno.2025.04.320.
- Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.
- Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.
- Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.
- McNamara B, Abozenah Y, Goreshnik A, Liu C, Altwerger G. Utility of positron emission tomography in preoperative inguinal lymph node assessment for vulvar cancer in the GROINS-VII/sentinel lymph node biopsy era: A single institution retrospective analysis. Gynecologic Oncology 2025, 200: s30. DOI: 10.1016/j.ygyno.2025.04.565.
- Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.
- Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.
- Greenman M, McNamara B, Ettorre V, Buza N, Azodi M. Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor. Gynecologic Oncology Reports 2025, 59: 101778. PMID: 40585380, PMCID: PMC12205314, DOI: 10.1016/j.gore.2025.101778.
- Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.
- Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.
- McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.
- Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.
- Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.
- Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.
- Vlamis C, Abozenah Y, Pebley N, Chang Y, McNamara B, Altwerger G. Laparoscopic pancreatic peritonectomy with splenectomy for recurrent ovarian cancer: a novel approach to achieve R0 while preserving the pancreatic body and tail. International Journal Of Gynecological Cancer 2024, 34: 1474-1475. PMID: 38724238, DOI: 10.1136/ijgc-2024-005358.
- McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.
- Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.
- Greenman M, McNamara B, Mutlu L, Santin A. Entering the golden age for antibody-drug conjugates in gynecologic cancer. Oncoscience 2024, 11: 51-52. PMID: 38770444, PMCID: PMC11104406, DOI: 10.18632/oncoscience.604.
- Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.
- Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.
- McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.
- Greenman M, McNamara B, Mutlu L, Santin A. Targeting cervical cancer with anti-PD-1 antibodies: what is new? Expert Opinion On Biological Therapy 2024, 24: 111-114. PMID: 38391293, DOI: 10.1080/14712598.2024.2323596.
- McNamara B, Greenman M, Pebley N, Mutlu L, Santin A. Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors. Molecules 2023, 28: 7389. PMID: 37959808, PMCID: PMC10650896, DOI: 10.3390/molecules28217389.
- AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
- Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, PMCID: PMC12626252, DOI: 10.1158/1535-7163.mct-23-0126.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
- McNamara B, Mutlu L, Greenman M, Harold J, Santin A. HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma. Cancers 2023, 15: 4085. PMID: 37627113, PMCID: PMC10452357, DOI: 10.3390/cancers15164085.
- McNamara B, Chang Y, Goreshnik A, Santin A. Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals. International Journal Of Women's Health 2023, 15: 1353-1365. PMID: 37663226, PMCID: PMC10474218, DOI: 10.2147/ijwh.s400537.
- Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.
- McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.
- Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
- Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich T, Harold J, Yang-Hartwich Y, Siegel E, Santin A. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. International Journal Of Molecular Sciences 2023, 24: 8873. PMID: 37240216, PMCID: PMC10219151, DOI: 10.3390/ijms24108873.
- McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
- Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
- McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.
- Han C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
- Mauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
- Manavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
- Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
- Mutlu L, Manavella D, Gullo G, McNamara B, Santin A, Patrizio P. Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes. Cancers 2022, 14: 5187. PMID: 36358604, PMCID: PMC9656291, DOI: 10.3390/cancers14215187.
- McNamara B, Joudeh L, Corbetta-Rastelli C, Orlando M, Kerns J. Traveling to California from out of state to receive abortion services at a hospital-based clinic: A qualitative study of people’s experiences. Sexual & Reproductive Healthcare 2022, 34: 100784. PMID: 36219955, DOI: 10.1016/j.srhc.2022.100784.
- McNamara B, Guerra R, Qin J, Craig A, Chen L, Varma M, Chapman J. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology Reports 2021, 38: 100870. PMID: 34646929, PMCID: PMC8496105, DOI: 10.1016/j.gore.2021.100870.
- Robledo-Gil T, Kemet S, Pensak M, Cutler A, McNamara B, Kennedy HP, Lundsberg L, Gariepy A. “Un abrazo a la distancia”: An Exploration of Spanish-Speaking Women’s Experiences with Pregnancy and Social Isolation in an Urban U.S. Setting. Hispanic Health Care International 2021, 20: 107-114. PMID: 34520260, DOI: 10.1177/15404153211041013.
- Webster E, Sartor R, Yadav G, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Ratner E, Altwerger G. Legal concerns and perceptions among women with gynecologic malignancies using prescribed medical cannabis: a single-institution, survey-based study. Gynecologic Oncology 2021, 162: s196-s197. DOI: 10.1016/s0090-8258(21)01023-4.
- Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan V, Menderes G, Huang G, Azodi M, Silasi DA, Santin AD, Schwartz PE, Ratner ES, Altwerger G. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study. Gynecologic Oncology Reports 2020, 34: 100667. PMID: 33204797, PMCID: PMC7653050, DOI: 10.1016/j.gore.2020.100667.
- Webster E, Dugan K, McNamara B, Lu L, Azodi M, Ratner E, Schwartz P, Menderes G. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study. Gynecologic Oncology 2020, 159: 131. DOI: 10.1016/j.ygyno.2020.05.163.
- Dugan K, McNamara B, Lu L, Litkouhi B, Azodi M, Schwartz P, Ratner E, Menderes G, Silasi D. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer. Gynecologic Oncology 2019, 154: 152. DOI: 10.1016/j.ygyno.2019.04.358.
- McNamara BC, Cutler A, Lundsberg L, Kennedy HP, Gariepy A. “I’m used to doing it by myself”: exploring self-reliance in pregnancy. BMC Pregnancy And Childbirth 2018, 18: 393. PMID: 30290785, PMCID: PMC6173858, DOI: 10.1186/s12884-018-2022-8.
- Kerns J, Light A, Dalton V, McNamara B, Steinauer J, Kuppermann M. Decision satisfaction among women choosing a method of pregnancy termination in the setting of fetal anomalies and other pregnancy complications: A qualitative study. Patient Education And Counseling 2018, 101: 1859-1864. PMID: 29980336, DOI: 10.1016/j.pec.2018.06.012.
- Kerns J, Mengesha B, McNamara B, Cassidy A, Pearlson G, Kuppermann M. Effect of counseling quality on anxiety, grief, and coping after second-trimester abortion for pregnancy complications. Contraception 2018, 97: 520-523. PMID: 29477632, DOI: 10.1016/j.contraception.2018.02.007.
- McNamara B, Russo J, Chaiken S, Jacobson J, Kerns J. A qualitative study of digoxin injection before dilation and evacuation. Contraception 2018, 97: 515-519. PMID: 29477630, DOI: 10.1016/j.contraception.2018.02.004.
- Cutler A, McNamara B, Qasba N, Kennedy HP, Lundsberg L, Gariepy A. “I Just Don't Know”: An Exploration of Women's Ambivalence about a New Pregnancy. Women's Health Issues 2017, 28: 75-81. PMID: 29108986, PMCID: PMC6223118, DOI: 10.1016/j.whi.2017.09.009.
- McNamara BC, Losikoff PT, Huguenin L, Macalino GE, Rich JD, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2014, 91: 376-82. PMID: 23722268, PMCID: PMC3978152, DOI: 10.1007/s11524-013-9807-x.
Departments and Programs
Locations
1
1 of 3
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Bridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecology OncologySmilow Cancer Hospital at Trumbull5520 Park Avenue, Ste 1-200Trumbull, CT 06611
1
1 of 3
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Bridgeport Hospital267 Grant StreetBridgeport, CT 06610
- Yale Gynecology OncologySmilow Cancer Hospital at Trumbull5520 Park Avenue, Ste 1-200Trumbull, CT 06611